^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer

Published date:
01/27/2022
Excerpt:
Eligible patients were HLA-A*02 positive with advanced NSCLC expressing MAGE-A10….Responses included: partial response (after second infusion; one patient), stable disease (four patients), clinical or radiographic progressive disease (five patients), and not evaluable (one patient)....The median PFS, OS, and DoSD were obtained for all patients after the first infusion. The median (range) PFS was 58 (1–89) days, with median (range) PFS for dose group 3 and the expansion group at 61 (52–88) days. The median (range) OS was 132 (10–458) days, with median (range) OS for dose group 3 and the expansion group at 211 (132–458) days. The median (range) overall DoSD was 61 (52–89) days....ADP-A2M10 demonstrated an acceptable safety profile and no evidence of toxicity related to off-target binding or alloreactivity.
DOI:
http://dx.doi.org/10.1136/jitc-2021-003581
Trial ID: